Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
NEJM study shows strong protection across strains
Hair care & quick commerce shine
Approval strengthens the company’s growing international anti-infective portfolio
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The Minister emphasised that scientific institutions must actively communicate their achievements and engage with stakeholders
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Report highlights growing confidence in digitalisation and AI, even as healthcare leaders remain concerned about workforce gaps, cybersecurity, and data readiness
Subscribe To Our Newsletter & Stay Updated
